Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.65 |
| ▸ | HSD17B1 | P14061 | 4/20 | 0.58 |
| ▸ | HSD17B2 | P37059 | 4/20 | 0.58 |
| ▸ | MAOB | P27338 | 14/20 | 0.58 |
| ▸ | DYRK1A | Q13627 | 1/20 | 0.56 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.56 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.56 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.56 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.56 |
| ▸ | CYP2B6 | P20813 | 1/20 | 0.56 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.56 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8403934 | 0.86 | HSD17B1 (0.65) | HSD17B1HSD17B2MAOBCYP1A2CYP3A4 | |
| SCHEMBL13805533 | 0.84 | HSD17B1 (0.55) | HSD17B1HSD17B2MAOBCYP1A2CYP3A4 | |
| SCHEMBL20832544 | 0.83 | ALDH1A1 (0.67) | ALDH1A1MAOB | |
| SCHEMBL4936252 | 0.83 | ALDH1A1 (0.63) | ALDH1A1CYP1A2CYP3A4CYP2C9 | |
| SCHEMBL7158014 | 0.83 | MAPT (0.64) | ALDH1A1HSD17B1HSD17B2MAOBDYRK1A | |
| SCHEMBL25221815 | 0.83 | ALDH1A1 (0.63) | ALDH1A1MAOBDYRK1A | |
| SCHEMBL30040343 | 0.83 | MAPT (0.64) | ALDH1A1MAOBDYRK1A | |
| SCHEMBL20899481 | 0.83 | ALDH1A1 (0.63) | ALDH1A1DYRK1ACYP1A2CYP3A4CYP2C9 | |
| SCHEMBL25219141 | 0.83 | MAPT (0.64) | ALDH1A1MAOBDYRK1A | |
| SCHEMBL30039055 | 0.83 | ALDH1A1 (0.63) | ALDH1A1MAOBDYRK1A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 52 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-112079769-A | Carboxamide compounds for the treatment of metabolic disorders | 里格尔药品股份有限公司 | 2020-12-15 | — | — | CN | disclosed |
| CN-106928211-B | Carboxamide compounds for the treatment of metabolic disorders | 里格尔药品股份有限公司 | 2020-09-08 | — | — | CN | disclosed |
| US-9353111-B2 | Carboxamide compounds and methods for using the same | RIGEL PHARMACEUTICALS, INC. (US) | 2016-05-31 | — | — | US | disclosed |
| US-9353111-B2 | Carboxamide compounds and methods for using the same | RIGEL PHARMACEUTICALS, INC. (US) | 2016-05-31 | — | — | US | disclosed |
| US-9353111-B2 | Carboxamide compounds and methods for using the same | RIGEL PHARMACEUTICALS, INC. (US) | 2016-05-31 | — | — | US | disclosed |
| US-20160122321-A1 | Carboxamide Compounds and Methods for Using the Same | MIDCAP FINANCIAL TRUST | 2016-05-05 | — | — | US | disclosed |
| US-20160122321-A1 | Carboxamide Compounds and Methods for Using the Same | MIDCAP FINANCIAL TRUST | 2016-05-05 | — | — | US | disclosed |
| US-20160122321-A1 | Carboxamide Compounds and Methods for Using the Same | MIDCAP FINANCIAL TRUST | 2016-05-05 | — | — | US | disclosed |
| US-9255085-B2 | Carboxamide compounds and methods for using the same | RIGEL PHARMACEUTICALS, INC. (US) | 2016-02-09 | — | — | US | disclosed |
| US-9255085-B2 | Carboxamide compounds and methods for using the same | RIGEL PHARMACEUTICALS, INC. (US) | 2016-02-09 | — | — | US | disclosed |
| US-20080261318-A1 | Signalling Compounds For Use In Methods Of Detecting Hydrogen Peroxide | LUMIGEN, INC. (US) | 2008-10-23 | — | — | US | disclosed |
| US-7390670-B2 | Signalling compounds and methods for detecting hydrogen peroxide | LUMIGEN, INC. (US) | 2008-06-24 | — | — | US | disclosed |
| EP-1594855-A4 | SIGNALLING COMPOUNDS FOR USE IN METHODS OF DETECTING HYDROGEN PEROXIDE | LUMIGEN INC (US) | 2008-04-16 | — | — | EP | disclosed |
| EP-1594855-A2 | SIGNALLING COMPOUNDS FOR USE IN METHODS OF DETECTING HYDROGEN PEROXIDE | LUMIGEN, INC. (US) | 2005-11-16 | — | — | EP | disclosed |
| US-6919463-B2 | Signalling compounds for use in methods of detecting hydrogen peroxide | LUMIGEN, INC. (US) | 2005-07-19 | — | — | US | disclosed |
| WO-2004074810-A2 | SIGNALLING COMPOUNDS FOR USE IN METHODS OF DETECTING HYDROGEN PEROXIDE | LUMIGEN INC. (US) | 2004-09-02 | — | — | WO | disclosed |
| US-20040171098-A1 | Signalling compounds for use in methods of detecting hydrogen peroxide | LUMIGEN INC. | 2004-09-02 | — | — | US | disclosed |
| US-20040166539-A1 | Signalling compounds and methods for detecting hydrogen peroxide | LUMIGEN, INC. | 2004-08-26 | — | — | US | disclosed |
| EP-1328514-A1 | AMIDE DERIVATIVES AS NMDA RECEPTOR ANTAGONISTS | RICHTER GEDEON VEGYESZETI GYAR R.T. (HU) | 2003-07-23 | — | — | EP | disclosed |
| WO-2002034718-A1 | AMIDE DERIVATIVES AS NMDA RECEPTOR ANTAGONISTS | RICHTER GEDEON VEGYESZETI GYAR RT. (HU) | 2002-05-02 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160122321-A1 | Carboxamide Compounds and Methods for Using the Same | PC, AK2, PRKAA2 | ALDH1A1 1247/4885HSD17B1 3915/4885HSD17B2 3710/4885 |
| US-20040171098-A1 | Signalling compounds for use in methods of detecting hydrogen peroxide | LPO, HAO2, HAO1 | ALDH1A1 252/4885HSD17B1 118/4885HSD17B2 143/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.